-- Retail Pharmacies, Including 900 Albertsons Locations, Added to the Provider Locator to Provide Injections of ARISTADA and VIVITROL; Additional Programs In Place to Deliver Support and Financial ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable ...

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care ...

The FDA (Food and Drug Administration) approved Aristada (Aripiprazole Lauroxil) partly on account of the drug’s clinical trials, which proved that patients using the treatment saw reductions in the ...

This potential new two-month offering would expand the range of ARISTADA dosing intervals to include a third option for patients with schizophrenia. ARISTADA was approved by the FDA in October 2015 as ...

— Novel Regimen Enables Physicians to Fully Dose Up to Two Months of ARISTADA Treatment on Day One — DUBLIN, July 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food ...

The most common adverse events reported in the ARISTADA treatment group were injection site pain (17.2%), increase in weight (9.1%) and akathisia (9.1%). The most common adverse events reported in the ...

The Food and Drug Administration has approved Alkermes long-acting injection treatment for schizophrenia. The drug, called Aristada, which is similar to Otsuka’s Abilify, is an injection administered ...

Pharmacists at these designated Albertsons Companies locations throughout the U.S. now are available to provide injections of ARISTADA and VIVITROL. These Albertsons sites extend Alkermes' existing ...

Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable suspension for the treatment of ...

The most common adverse events reported in the ARISTADA treatment group were injection site pain (17.2%), increase in weight (9.1%) and akathisia (9.1%). The most common adverse events reported in the ...